Edition:
India

Unum Therapeutics Inc (UMRX.OQ)

UMRX.OQ on NASDAQ Stock Exchange Global Select Market

11.98USD
20 Apr 2018
Change (% chg)

-- (--)
Prev Close
$11.98
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
--
52-wk High
$12.25
52-wk Low
$10.50

Summary

Name Age Since Current Position

Charles Wilson

Founder, President, Chief Executive Officer and Director

Dario Campana

Scientific Founder

Christiana Stamoulis

47 2015 Chief Financial Officer, Head - Corporate Development

Seth Ettenberg

Chief Scientific Officer

Ben Auspitz

Director

Bruce Booth

Director

Biographies

Name Description

Charles Wilson

Dr. Charles Wilson, Ph.D. is the Founder, President, Chief Executive Officer and Director of the company. Before founding Unum, Dr. Wilson led the team responsible for partnering to support research and early development at Novartis. With many oncology and immuno-oncology deals to his credit, he brings extensive experience to Unum spanning from early drug discovery through Phase II clinical development. Prior to Novartis, Dr. Wilson held both scientific and business management roles in biotech.

Dario Campana

Dr. Dario Campana, M.D. Ph.D. is the Scientific Founder of the company. Dr. Campana is an established leader in the field of cancer cell therapies. At the National University of Singapore (NUS), he developed the ACTR technology that forms the basis for Unum. At St. Jude Children’s Research Hospital (Memphis, TN), he created a chimeric antigen receptor (CAR) approach that is currently being pursued by several pharma and biotech companies. He currently oversees a number of cell therapy clinical trials in oncology.

Christiana Stamoulis

Ms. Christiana Stamoulis is Chief Financial Officer, Head - Corporate Development of the Company. Ms. Stamoulis has nearly 20 years of experience in the biotechnology industry as a senior executive and a strategic and corporate finance advisor to CEOs and Boards of Directors of global biopharmaceutical companies. She has extensive experience in developing strategies for sustainable growth and executing complex M&A deals, strategic collaborations and capital-raising transactions with aggregate value in excess of $100 billion. Most recently, Ms. Stamoulis was the Senior Vice President and Head of Corporate Strategy and Business Development at Vertex Pharmaceuticals, where she helped develop the company's vision and led its efforts to form strategic business collaborations. Prior to Vertex, she was a Managing Director in Citigroup's Investment Banking division and a senior investment banker at Goldman, Sachs & Co's Healthcare Investment Banking Group, where she spent the majority of her investment banking career. Ms. Stamoulis graduated from the MIT Sloan School of Management with a Master degree in Business Administration. She also has Bachelor of Science degrees in Economics and Architecture from the Massachusetts Institute of Technology. She currently serves as a director of the Board of Hologic, a leading global developer and supplier of diagnostic products, medical imaging systems and surgical products.

Seth Ettenberg

Dr. Seth Ettenberg, Ph.D. is the Chief Scientific Officer of the company. He is a cancer biologist and drug development scientist with extensive experience leading teams in biotechnology and large pharmaceutical drug discovery settings. Dr. Ettenberg most recently served as the Cambridge site head for Novartis Oncology Biotherapeutics.

Ben Auspitz

Bruce Booth

Basic Compensation

Options Compensation